349-55-3

Basic information

• Product Name: 3-Methoxy-5-(trifluoromethyl)aniline
• Synonyms: 3-(trifluoromethyl)-5-methoxybenzenamine;3-Methoxy-5-(trifluoromethyl)aniline, 5-Methoxy-alpha,alpha,alpha-trifluoro-m-toluidine, 5-(Trifluoromethyl)-m-anisidine;3-AMino-5-(trifluoroMethyl)anisole[3-Methoxy-5-(trifluoroMethyl)aniline];Benzenamine, 3-methoxy-5-(trifluoromethyl)-;3-Methoxy-5-(trifluoromethyl)anil;3-METHOXY-5-TRIFLUOROMETHYL-PHENYLAMINE;3-METHOXY-5-(TRIFLUOROMETHYL)ANILINE;3-AMINO-5-METHOXYBENZOTRIFLUORIDE
• CAS NO: 349-55-3
• Molecular Formula: C₈H₈F₃NO
• Molecular Weight: 191.15
• EINECS: 206-487-8
• Product Categories: NULL;Amines and Anilines;Anilines, Aromatic Amines and Nitro Compounds
• Mol File: 349-55-3.mol

Chemical Properties

• Melting Point: 50-52 °C(lit.)
• Boiling Point: 242 °C at 760 mmHg
• Flash Point: >230 °F
• Appearance: /
• Density: 1.28 g/cm³
• Vapor Pressure: 0.0348mmHg at 25°C
• Refractive Index: 1.476
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 2.95±0.10(Predicted)
• CAS DataBase Reference: 3-Methoxy-5-(trifluoromethyl)aniline(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Methoxy-5-(trifluoromethyl)aniline(349-55-3)
• EPA Substance Registry System: 3-Methoxy-5-(trifluoromethyl)aniline(349-55-3)

Safety Data

• Hazard Codes: Xn
• Statements: 20/21/22-36/37/38-23-22
• Safety Statements: 26-37/39-24/25
• RIDADR: PG3
• WGK Germany: 3
• HazardClass: 6.1
• Hazardous Substances Data: 349-55-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-Methoxy-5-(trifluoromethyl)aniline is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its specific application is in the production of spleen tyrosine kinase inhibitors, which are based on the phenylamino pyrimidine thiazole structure. These inhibitors play a crucial role in the development of treatments for various diseases, including autoimmune disorders and cancer, by targeting the spleen tyrosine kinase enzyme.

InChI:InChI=1/C8H8F3NO/c1-13-7-3-5(8(9,10)11)2-6(12)4-7/h2-4H,12H2,1H3

Upstream product

• 328-79-0 1-methoxy-3-nitro-5-trifluoromethyl-benzene 
• 402-07-3 1-bromo-2-methoxy-4-(trifluoromethyl)benzene 
• 7664-41-7 ammonia 
• 401-99-0 3,5-dinitrobenzotrifluoride 

Downstream Products

• 401-86-5 3-amino-5-(1,1,1-trilfluoromethyl)phenol 
• 62606-09-1 (3-Methoxy-5-trifluoromethyl-phenyl)-(2,4,6-trinitro-phenyl)-amine 
• 943722-82-5 C₁₇H₂₂F₃NO₂ 

Relevant articles and documents

2,3-DIHYDROIMIDAZO[1 ,2-c] PYRIMIDIN-5(1 H)-ONE COMPOUNDS USE AS LP-PLA2 INHIBITORS

Disclosed are 2,3-dihydroimidazo[1,2-c]pyrimidin-5(1H)-one compounds that inhibit Lp-PLA2, processes for their preparation, compositions containing them and their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease.

2,3-DIHYDROIMIDAZO[1,2-C] PYRIMIDIN-5(1H)-ONE COMPOUNDS USE AS LP-PLA2 INHIBITORS

Disclosed are 2,3-dihydroimidazo[1,2-c]pyrimidin-5(1H)-one compounds that inhibit Lp-PLA2, processes for their preparation, compositions containing them and their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer?s disease

QUINOLINE UROTENSIN-II RECEPTOR ANTAGONISTS

Provided are compounds that are modulators of urotensin-II receptor activity, compositions containing the compounds and methods of use of the compounds and compositions. In certain embodiments, provided are methods for treating or ameliorating diseases associated with modulation of urotensin-II receptor activity.

PYRIMIDINYL ARYL UREA DERIVATIVES BEING FGF INHIBITORS

The invention relates to heteroaryl aryl ureas of the formula (IA), wherein the radicals and symbols have the meanings as defined herein, the use of such compounds in the treatment of protein kinase dependent diseases; to pharmaceutical preparations comprising said heteroaryl aryl ureas, to processes for the manufacture of such novel compounds and to methods of treatment comprising the use of such heteroaryl aryl ureas.

Palladium-catalyzed silane/siloxane reductions in the one-pot conversion of nitro compounds into their amines, hydroxylamines, amides, sulfonamides, and carbamates

A combination of palladium(II) acetate, aqueous potassium fluoride, and polymethylhydrosiloxane (PMHS) facilitates the room-temperature reduction of aromatic nitro compounds to anilines. These reactions tend to be quick (30 min), high-yielding, and tolerate a range of other functional groups. Replacement of PMHS/KF with triethylsilane allows for the reduction of aliphatic nitro compounds to their corresponding hydroxylamines. Depending on the substrate, both conditions can allow for the in situ conversion of the product amines into amides, sulfonamides, and carbamates. Georg Thieme Verlag Stuttgart.

Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists

The present invention relates to urotensin II receptor antagonists, pharmaceutical compositions containing them and their use.